AngioDynamics's 15min chart triggers KDJ Death Cross and Bearish Marubozu signal.

AngioDynamics's 15-minute chart has recently triggered a KDJ Death Cross and a Bearish Marubozu, which indicates a shift in momentum towards the downside. This suggests that the stock price may continue to decrease, as sellers currently dominate the market. The bearish momentum is expected to persist, indicating a negative trend in the company's financial performance.

AngioDynamics Inc. (ANGO) reported its first-quarter fiscal 2026 results, showing mixed financial performance. Net sales increased by 12.2% to $75.7 million, driven by a 26.1% growth in Med Tech revenue, led by Auryon, NanoKnife, and thrombus management products. Med Device revenue grew modestly by 2.3%. The company's gross margin improved by 90 basis points to 55.3% [10-Q] ANGIODYNAMICS INC Quarterly Earnings Report^[1].

Despite the revenue growth, AngioDynamics recorded a net loss of $10.9 million, a significant improvement from the prior year's loss of $12.8 million. The company continues to restructure its operations, with $2.3 million in charges recorded this quarter and a total of $25.6 million recorded to date. A settlement with BD (Becton, Dickinson) includes a one-time lump-sum payment of $2.5 million and ongoing minimum annual payments, with a contingent $3.0 million potentially due depending on the Federal Circuit appeal [10-Q] ANGIODYNAMICS INC Quarterly Earnings Report^[1].

Technical indicators for AngioDynamics' stock have recently shown bearish signs. The 15-minute chart has triggered a KDJ Death Cross and a Bearish Marubozu, suggesting a shift in momentum towards the downside. This indicates that sellers currently dominate the market, and the stock price may continue to decrease. The bearish momentum is expected to persist, indicating a negative trend in the company's financial performance .

AngioDynamics has a $25.0 million revolving credit facility with $0 drawn as of August 31, 2025, providing liquidity optionality. However, management has flagged ongoing macroeconomic risks, supply-chain pressures, and inflation as potential challenges that could affect cash flow and margins [10-Q] ANGIODYNAMICS INC Quarterly Earnings Report^[1].

The company is also defending approximately 219 Port Product Claims consolidated for pretrial proceedings, which could materially affect estimates if additional claims emerge or details change [10-Q] ANGIODYNAMICS INC Quarterly Earnings Report^[1].